Industry News
Biotechnology Industry News
Bridging the preclinical to clinical divide: practical considerations for biomarker success
Bridging the preclinical to clinical divide: practical considerations for biomarker success mwen Thu, 03/17/2022 - 09:29
Silence stops enrollment in blood cancer arm of RNAi trial over ‘recruitment challenges’
Silence stops enrollment in blood cancer arm of RNAi trial over 'recruitment challenges' ntaylor Thu, 03/17/2022 - 08:34
AstraZeneca throws open doors to new ideas in global postdoc challenge
AstraZeneca throws open doors to new ideas in global postdoc challenge ntaylor Thu, 03/17/2022 - 06:36
Eiger eager to send COVID-19 drug to FDA after hospitalizations, deaths slashed—including against omicron
Eiger eager to send COVID-19 drug to FDA after hospitalizations, deaths slashed—including against omicron klahucik Wed, 03/16/2022 - 14:53
Shionogi’s COVID-19 antiviral heads to phase 3 backed by NIH after receiving FDA go-ahead
Shionogi's COVID-19 antiviral heads to phase 3 backed by NIH after receiving FDA go-ahead aarmstrong Wed, 03/16/2022 - 14:21
MIT-made COVID-19 vax produced by yeast could address global vaccine inequity
MIT-made COVID-19 vax produced by yeast could address global vaccine inequity mbayer Wed, 03/16/2022 - 11:18
FDA’s gene editing guidance is ‘par for the course’ but still important, analysts say
FDA's gene editing guidance is 'par for the course' but still important, analysts say aarmstrong Wed, 03/16/2022 - 09:43
With clinical holds lifted, Aprea embarks on ‘show me’ year for key cancer candidate
With clinical holds lifted, Aprea embarks on 'show me' year for key cancer candidate klahucik Wed, 03/16/2022 - 09:12
Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality
Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality ntaylor Wed, 03/16/2022 - 07:29
Biogen jettisons AMD drug, providing Catalyst for ex-partner’s hunt for strategic alternatives
Biogen jettisons AMD drug, providing Catalyst for ex-partner's hunt for strategic alternatives ntaylor Wed, 03/16/2022 - 04:11
With $987M round, Frazier looks to form several new biotechs this year, bankroll others
With $987M round, Frazier looks to form several new biotechs this year, bankroll others klahucik Tue, 03/15/2022 - 16:04
Belgian biotech Precirix snags $88M to bankroll radiopharmaceuticals in HER2-positive cancers
Belgian biotech Precirix snags $88M to bankroll radiopharmaceuticals in HER2-positive cancers klahucik Tue, 03/15/2022 - 15:01
Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb
Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb mwen Tue, 03/15/2022 - 14:19
Ovid finds new focus in epilepsy but trims staff to extend cash runway
Ovid finds new focus in epilepsy but trims staff to extend cash runway mbayer Tue, 03/15/2022 - 14:12
Zai Lab hires ex-Lilly CFO who departed after investigation found ‘inappropriate’ behavior
Zai Lab hires ex-Lilly CFO who departed after investigation found 'inappropriate' behavior klahucik Tue, 03/15/2022 - 11:23
Passage Bio chips away at workforce, prioritizes R&D with UPenn’s James Wilson
Passage Bio chips away at workforce, prioritizes R&D with UPenn's James Wilson mbayer Tue, 03/15/2022 - 10:09
AbbVie, eyeing shift to endemic, adds to COVID-19 work with Scripps partnership
AbbVie, eyeing shift to endemic, adds to COVID-19 work with Scripps partnership klahucik Tue, 03/15/2022 - 09:54
Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciences
Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciences klahucik Tue, 03/15/2022 - 08:59
Astellas’ menopause drug suffers rare setback as failed Asian trial blots previously pristine record
Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record ntaylor Tue, 03/15/2022 - 07:43
AnaptysBio’s ACORN fails to grow mighty oak, marking end of development of imsidolimab in acne
AnaptysBio's ACORN fails to grow mighty oak, marking end of development of imsidolimab in acne ntaylor Tue, 03/15/2022 - 06:41